454 Life Sciences
|Founder||Jonathan M. Rothberg|
|Headquarters||Branford, Connecticut, USA|
|Products||Genome sequencers, reagents|
|Services||Sequencing of genetic samples|
|Parent||Roche Applied Science|
- 1 History and major achievements
- 2 Ownership
- 3 First human DNA sequence
- 4 Technology
- 5 Applications
- 6 Patents awarded
- 7 See also
- 8 Notes
- 9 General references
- 10 External links
History and major achievements
454 Life Sciences was founded by Jonathan Rothberg originally as 454 Corporation, a subsidiary of CuraGen Corporation. For their method for low-cost gene sequencing, 454 Life Sciences were awarded the Wall Street Journal's Gold Medal for Innovation in the Biotech-Medical category in 2005. The name 454 was the code name by which the project was referred to at CuraGen and the numbers have no special meaning.
In November 2006, Rothberg, Michael Egholm, and colleagues at 454 published a cover article with Svante Pääbo in Nature describing the first million base pairs of the Neanderthal genome, and initiated the Neanderthal Genome Project to complete the sequence of the Neanderthal genome by 2009.
In late March 2007, Roche Diagnostics announced an agreement to purchase 454 Life Sciences for US$154.9 million. It will remain a separate business unit. In October 2013, Roche announced that it will shut down 454, and stop supporting the platform by mid-2016.
First human DNA sequence
In May 2007, Project "Jim", a project initiated by Rothberg and 454 Life Sciences to determine the first sequence of an individual was completed after sequencing the genome of James Watson, co-discoverer of the structure of DNA.
454 Sequencing uses a large-scale parallel pyrosequencing system capable of sequencing roughly 400-600 megabases of DNA per 10-hour run on the Genome Sequencer FLX with GS FLX Titanium series reagents.
The system relies on fixing nebulized and adapter-ligated DNA fragments to small DNA-capture beads in a water-in-oil emulsion. The DNA fixed to these beads is then amplified by PCR. Each DNA-bound bead is placed into a ~29 μm well on a PicoTiterPlate, a fiber optic chip. A mix of enzymes such as DNA polymerase, ATP sulfurylase, and luciferase are also packed into the well. The PicoTiterPlate is then placed into the GS FLX System for sequencing.
454 has experienced rapid growth since its acquisition by Roche Diagnostics and release of the GS20 sequencing machine in 2005, the first next-generation DNA sequencer on the market. In 2008, 454 Sequencing launched the GS FLX Titanium series reagents for use on the Genome Sequencer FLX instrument, with the ability to sequence 400-600 million base pairs per run with 400-500 base pair read lengths. The company has said it plans to launch kits enabling sequencing read lengths of up to 1,000 bp in 2010. In late 2009, 454 Life Sciences introduced the GS Junior System, a bench top version of the Genome Sequencer FLX System.
DNA library preparation and emPCR
Genomic DNA is fractionated into smaller fragments (300-800 base pairs) and polished (made blunt at each end). Short adaptors are then ligated onto the ends of the fragments. These adaptors provide priming sequences for both amplification and sequencing of the sample-library fragments. One adaptor (Adaptor B) contains a 5'-biotin tag for immobilization of the DNA library onto streptavidin-coated beads. After nick repair, the non-biotinylated strand is released and used as a single-stranded template DNA (sstDNA) library. The sstDNA library is assessed for its quality and the optimal amount (DNA copies per bead) needed for emPCR is determined by titration.
The sstDNA library is immobilized onto beads. The beads containing a library fragment carry a single sstDNA molecule. The bead-bound library is emulsified with the amplification reagents in a water-in-oil mixture. Each bead is captured within its own microreactor where PCR amplification occurs. This results in bead-immobilized, clonally amplified DNA fragments.
Single-stranded template DNA library beads are added to the DNA Bead Incubation Mix (containing DNA polymerase) and are layered with Enzyme Beads (containing sulfurylase and luciferase) onto a PicoTiterPlate device. The device is centrifuged to deposit the beads into the wells. The layer of Enzyme Beads ensures that the DNA beads remain positioned in the wells during the sequencing reaction. The bead-deposition process is designed to maximize the number of wells that contain a single amplified library bead.
The loaded PicoTiterPlate device is placed into the Genome Sequencer FLX Instrument. The fluidics sub-system delivers sequencing reagents (containing buffers and nucleotides) across the wells of the plate. The four DNA nucleotides are added sequentially in a fixed order across the PicoTiterPlate device during a sequencing run. During the nucleotide flow, millions of copies of DNA bound to each of the beads are sequenced in parallel. When a nucleotide complementary to the template strand is added into a well, the polymerase extends the existing DNA strand by adding nucleotide(s). Addition of one (or more) nucleotide(s) generates a light signal that is recorded by the CCD camera in the instrument. This technique is based on sequencing-by-synthesis and is called pyrosequencing. The signal strength is proportional to the number of nucleotides; for example, homopolymer stretches, incorporated in a single nucleotide flow generate a greater signal than single nucleotides. However, the signal strength for homopolymer stretches is linear only up to eight consecutive nucleotides after which the signal falls-off rapidly. Data are stored in standard flowgram format (SFF) files for downstream analysis.
454 Sequencing can sequence any double-stranded DNA and enables a variety of applications including de novo whole genome sequencing, re-sequencing of whole genomes and target DNA regions, metagenomics and RNA analysis.
Full genome sequencing (de novo sequencing and resequencing)
Full genome sequencing (FGS), also referred to as whole genome sequencing (WGS), aims to sequence the entire genome of an organism, for example, humans, dogs, mice, viruses or bacteria. In June 2006, 454 Life Sciences launched a project with the Max Planck Institute for Evolutionary Anthropology to sequence the genome of the Neanderthal, the extinct closest relative of humans. In September 2008 the complete Neanderthal mitochondrial genome was sequenced, establishing the divergence between humans and Neanderthal at 660,000 ± 140,000 years, and the full genome was published in 2010, using a combination of 454 and Illumina sequencing.
Amplicon (ultra deep) sequencing is a new field which is largely being enabled through 454 Sequencing technology. This method is designed to allow mutations to be detected at extremely low levels, and PCR amplify specific, targeted regions of DNA. This method is used to identify low frequency somatic mutations in cancer samples or discovery of rare variants in HIV infected individuals.
Transcriptome sequencing encompasses experiments including small RNA profiling and discovery, mRNA transcript expression analysis (full-length mRNA, expressed sequence tags (ESTs) and ditags, and allele-specific expression) and the sequencing and analysis of full-length mRNA transcripts. Often these sequencing methods employ the de novo assembly approach. The transcriptome data derived from the Genome Sequencer FLX is ideally suited to detailed transcriptome investigation in the areas of novel gene discovery, gene space identification in novel genomes, assembly of full-length genes, single nucleotide polymorphism (SNP), insertion-deletion and splice-variant discovery.
Metagenomics is the study of the genomic content in a complex sample. The two primary goals of this approach are to characterize the organisms present in a sample and identify what roles each organism has within a specific environment. Metagenomics samples are found nearly everywhere, including several microenvironments within the human body, soil samples, extreme environments such as deep mines and the various layers within the ocean. The Genome Sequencer FLX System enables a comprehensive view into the diversity of an environmental habitat. The system’s long reads ensure the enormous specificity needed to compare sequenced reads against DNA or protein databases. The platform is used to count environmental gene tags to analyze the relative abundance of microbial species under varying environmental conditions.
||This article is in a list format that may be better presented using prose. (December 2009)|
- Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
- Method of sequencing a nucleic acid
- Double ended sequencing
- Method of sequencing a nucleic acid
- Apparatus and method for sequencing a nucleic acid
- Totty, Michael (October 24, 2005). "A Better Idea". The Wall Street Journal.
- Pollack, Andrew (August 22, 2003). "Company Says It Mapped Genes of Virus in One Day". The New York Times.
- Wheeler, D. A.; Srinivasan, M.; Egholm, M.; Shen, Y.; Chen, L.; McGuire, A.; He, W.; Chen, Y. J.; Makhijani, V.; Roth, G. T.; Gomes, X.; Tartaro, K.; Niazi, F.; Turcotte, C. L.; Irzyk, G. P.; Lupski, J. R.; Chinault, C.; Song, X.-Z.; Liu, Y.; Yuan, Y.; Nazareth, L.; Qin, X.; Muzny, D. M.; Margulies, M.; Weinstock, G. M.; Gibbs, R. A.; Rothberg, J. M. (2008). "The complete genome of an individual by massively parallel DNA sequencing". Nature 452 (7189): 872–876. doi:10.1038/nature06884. PMID 18421352.
- "Project Jim: Watson’s Personal Genome Goes Public".
- Karl, V et al. (2009). "Next Generation Sequencing: From Basic Research to Diagnostics". Clinical Chemistry 55 (4): 41–47. doi:10.1373/clinchem.2008.112789. PMID 19246620.
- "454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010" (Press release). 454 Life Sciences. November 19, 2009. Retrieved November 19, 2009.
- Zheng, Z et al. (2010). "Titration-free massively parallel pyrosequencing using trace amounts of starting material". Nucleic Acids Res 38 (13): e137. doi:10.1093/nar/gkq332. PMC 2910068. PMID 20435675.
- King, C; Scott-Horton, T. (2008). "Pyrosequencing: a simple method for accurate genotyping". J Vis Exp (11). doi:10.3791/630. PMC 2582836. PMID 19066560.
- Margulies, Marcel; Michael Egholm; 54 additional coauthors (September 15, 2005). "Genome Sequencing in Open Microfabricated High Density Picoliter Reactors". Nature (Nature Publishing Group) 437 (7057): 376–380. Bibcode:2005Natur.437..376M. doi:10.1038/nature03959. PMC 1464427. PMID 16056220.
- "454 Life Sciences and Max Planck Institute to Sequence Neandertal Genome" (Press release). 454 Life Sciences. July 20, 2006. Retrieved December 16, 2007.
- "Neandertal Genome to be Deciphered" (Press release). Max Planck Society. July 20, 2006. Retrieved December 16, 2007.
- Green, Richard E. et al. (August 8, 2008). "A complete Neandertal Mitochondrial Genome Sequence Determined by High-Throughput Sequencing" (PDF). Cell (Elsevier) 134 (3): 416–426. doi:10.1016/j.cell.2008.06.021. PMC 2602844. PMID 18692465.
- Green, Richard E. et al. (May 7, 2010). "A Draft Sequence of the Neandertal Genome". Science (AAAS) 328 (5979): 710–722. Bibcode:2010Sci...328..710G. doi:10.1126/science.1188021. PMID 20448178.
A complete listing of peer-reviewed research articles can be found on the Roche/454 Sequencing website :
- Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Research.
- Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Human Genetics.
- A new arenavirus in a cluster of fatal transplant-associated diseases. New England Journal of Medicine.
- A Sequencing Method Based on Real-Time Pyrophosphate Release
- Analysis of one million base pairs of Neanderthal DNA. Nature
- Genome of DNA Discoverer Is Deciphered. New York Times
- Dana Farber and 454 Life Sciences Announce Breakthrough in DNA Sequencing for Cancer Research
- Sogin et al. Microbial diversity in the deep sea and the underexplored "rare biosphere". PNAS. 31 July 2006.
- CuraGen Announces Definitive Agreement to Sell 454 Life Sciences to Roche